Information:
Fel:
ID
37000
Beskrivning
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT02207530
Länk
https://clinicaltrials.gov/show/NCT02207530
Nyckelord
Versioner (1)
- 2019-06-27 2019-06-27 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
27 juni 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCT02207530
Eligibility Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCT02207530
Similar models
Eligibility Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCT02207530
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
age ≥18 years;
boolean
C0001779 (UMLS CUI [1])
Informed Consent | Informed Consent Patient Representative
Item
written informed consent obtained from the patient/legal representative;
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma
Item
histologically confirmed recurrent or metastatic scchn;
boolean
C4524839 (UMLS CUI [1])
C0744620 (UMLS CUI [2])
C0744620 (UMLS CUI [2])
Squamous cell carcinoma of the head and neck PD-L1 Positive Immunohistochemistry
Item
confirmed pd-l1-positive scchn by a specified ihc assay;
boolean
C1168401 (UMLS CUI [1,1])
C4284303 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C4284303 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
Tumor Progression | Recurrent tumor | Systemic therapy Containing Platinum | Recurrent disease | Neoplasm Metastasis
Item
tumor progression or recurrence during or after treatment with one systemic regimen for recurrent or metastatic disease that must have contained a platinum agent;
boolean
C0178874 (UMLS CUI [1])
C0521158 (UMLS CUI [2])
C1515119 (UMLS CUI [3,1])
C0332256 (UMLS CUI [3,2])
C0032207 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4])
C0027627 (UMLS CUI [5])
C0521158 (UMLS CUI [2])
C1515119 (UMLS CUI [3,1])
C0332256 (UMLS CUI [3,2])
C0032207 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4])
C0027627 (UMLS CUI [5])
WHO performance status scale
Item
who performance status of 0 or 1;
boolean
C1298650 (UMLS CUI [1])
Measurable lesion Quantity
Item
at least 1 measurable lesion at baseline
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Chemotherapy | Therapies, Investigational | Biological treatment | Hormone Therapy | Cancer treatment
Item
any concurrent chemotherapy, ip, biologic, or hormonal therapy for cancer treatment;
boolean
C0392920 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
C0920425 (UMLS CUI [5])
C0949266 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
C0920425 (UMLS CUI [5])
Major surgery
Item
major surgical procedure within 28 days prior to the first dose of ip;
boolean
C0679637 (UMLS CUI [1])
Non-squamous cell Histology
Item
non-squamous histologies;
boolean
C1545484 (UMLS CUI [1,1])
C0344441 (UMLS CUI [1,2])
C0344441 (UMLS CUI [1,2])
Primary immunodeficiency
Item
history of active primary immunodeficiency;
boolean
C0398686 (UMLS CUI [1])
Autoimmune Disease | Inflammatory disorder
Item
active or prior documented autoimmune or inflammatory disorders
boolean
C0004364 (UMLS CUI [1])
C1290884 (UMLS CUI [2])
C1290884 (UMLS CUI [2])